Cinctive Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Cinctive Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.3M	Buy	26,712 +21,663	+429%	+$9.6M	0.49%	55
2026 Q1	$2.25M	Buy	+5,049	New	+$2.35M	0.15%	196
2025 Q2	–	Sell	-13,891	Closed	-$6.73M	–	477
2025 Q1	$6.73M	Buy	+13,891	New	+$6.47M	0.52%	58
2022 Q3	–	Sell	-11,375	Closed	-$3.21M	–	628
2022 Q2	$3.21M	Buy	+11,375	New	+$3.04M	0.13%	241
2022 Q1	–	Sell	-5,155	Closed	-$1.13M	–	672
2021 Q4	$1.13M	Buy	+5,155	New	+$1M	0.05%	389
2020 Q4	–	Sell	-12,467	Closed	-$3.39M	–	409
2020 Q3	$3.39M	Sell	12,467 -10,613	-46%	-$2.93M	0.3%	139
2020 Q2	$6.7M	Buy	23,080 +14,699	+175%	+$3.99M	0.77%	18
2020 Q1	$1.99M	Sell	8,381 -18,719	-69%	-$4.29M	0.44%	92
2019 Q4	$5.93M	Buy	+27,100	New	+$5.48M	0.62%	62

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Cinctive Capital Management's VRTX Position: Q2 2026 in Review

Cinctive Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 429% in Q2 2026, buying an estimated $9.6M and bringing the position to 26,712 shares worth $13.3M. The position accounts for 0.49% of the portfolio, ranked #55.

Cinctive Capital Management first reported a position in VRTX in Q4 2019 and has held it in 9 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Cinctive Capital Management held 26,712 shares of Vertex Pharmaceuticals worth $13.3M as of Q2 2026.
Cinctive Capital Management bought 21,663 Vertex Pharmaceuticals shares in Q2 2026, an estimated $9.6M.
Vertex Pharmaceuticals made up 0.49% of Cinctive Capital Management's portfolio in Q2 2026, its #55 holding.
Cinctive Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2019 and has held it in 9 quarters since.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Cinctive Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.